Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40 results about "DNA Methylation Site" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
GC tag-modified bisulfite genomic DNA sequencing for continuous methylation spectra
InactiveUS20070054295A1Avoid the needMicrobiological testing/measurementFermentationGenomic sequencingCycle sequencing
The present invention relates to a tag-modified bisulfite genomic sequencing (tBGS) method developed for simplified evaluation of DNA methylation sites. The method employs direct cycle sequencing of PCR products at kilobase scale, without conventional DNA fragment cloning. The method entails subjecting bisulfite-modified genomic DNA to a second-round PCR amplification employing GC-tagged primers. The invention also relates to a method for identifying a patient at risk for lung cancer using the tBGS technique disclosed.
Owner:SPIVACK SIMON DANIEL +2
Method, marker, and kit used for colorectal cancer diagnosis, screening, and risk prediction
ActiveCN108315418AEasy to detectLow costMicrobiological testing/measurementDNA/RNA fragmentationCpG siteComputer module
The invention discloses a DNA methylation marker used for diagnosis, screening, and prediction of male colorectal cancer. The DNA methylation marker is obtained via methylation of a combination of thefirst groups, or the first group with the second group, or the third groups, (1), +22, +27, and +29; (2), -24,-18, +89, and +92; and (3) +136; of three CpG sites in the front and back sequence of gene RPS24 transcription start site. The sequence number is based on sequence number in SEQ ID NO.1. The 143th site transcription start site A is recorded as +1. The invention also discloses a probe, a method, and a kit used for detecting the DNA methylation marker, and a computer module used for prediction of male colorectal cancer risk using the data of the DNA methylation sites.
Owner:太科航天智能康养技术(深圳)有限责任公司
DNA (Deoxyribonucleic Acid) methylation indicator for early diagnosis of cancers and hazard degree assessment and application thereof
The invention relates to a method for cancer diagnosis and / or cancer risk hazard degree assessment in subjects. The method comprises the following steps: a) determining DNA methylation states of samples from the subjects and samples from a healthy control group on at least one DNA methylation site; b) comparing the DNA methylation states of the samples from the subjects at the DNA methylation site with the DNA methylation states of the samples from the healthy control group at the corresponding DNA methylation site; and if the methylation states of the samples from the subjects and the samples from the healthy control group have remarkable difference, showing that the subjects have cancers or have cancer risks. The invention further provides a kit for the method provided by the invention.
Owner:TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
DNA (Deoxyribonucleic Acid) methylation marker for evaluating early abortion risk, primer and application thereof
ActiveCN108315410AEasy to detectQuantitatively accurateMicrobiological testing/measurementDNA/RNA fragmentationTranscription initiationPRDM1
The invention belongs to the field of the genetic engineering, and particularly provides a blood DNA (Deoxyribonucleic Acid) methylation marker for evaluating an early abortion risk, a primer and theapplication thereof. The DNA methylation marker comprises eight DNA methylation sites positioned near a PRDM1 gene transcription starting area: cg25608130, cg19577529, cg10573915, cg11072009, cg02667677, cg23778363, cg24793124 and cg07331652. The successful development of the category of the differentiated DNA methylation biological marker is the overturn of a traditional biomarker which gives a priority to protein, a brand new situation is started for diagnosing, preventing and curing the early abortion, and a reference is provided for researching the biomarkers of other diseases. The DNA methylation marker has the advantages of abundant raw materials and convenience in operation and is the biomarker with prospect.
Owner:NANJING MEDICAL UNIV
DNA methylation biomarkers for evaluating cardiac muscle cell damage and application thereof
InactiveCN107828884AIncreased sensitivityImprove featuresMicrobiological testing/measurementDNA/RNA fragmentationBiomarker (petroleum)Cells heart
The invention belongs to the field of the genetic engineering, and particularly provides a group of DNA methylation biomarkers for evaluating cardiac muscle cell damage and an application thereof. TheDNA methylation biomarker comprises 30 DNA methylation sites of 5 DMRs corresponding to 5 cardiac muscle differentiation key factors; and the five cardiac muscle differentiation key factors are GATA4, TNNT2, TNNI3, MEF2A and NKX2-5. Such type of the provided differential DNA methylation biomarkers is successfully developed to subvert the traditional biomarkers using protein as major means, a newsituation is created for the prevention and treatment of the cardiac muscle damage, and a reference is provided for the development of other disease biomarkers. The DNA methylation biomarkers are capable of evaluating the damage level of the cardiac muscle affected by environmental factors, and evaluating and forecasting the cardiotoxicity of environmental chemistry, and are the biomarkers with the prospect.
Owner:NANJING MEDICAL UNIV
Dimensionality reduction method of DNA methylation spectrum for gastric cancer
ActiveCN109859796ADimensionality reduction is effectiveDimensionality reduction analysis worksProteomicsGenomicsDimensionality reductionDrug development
The invention discloses a dimensionality reduction method of DNA methylation spectrum for gastric cancer. The dimensionality reduction method includes the steps: selecting statistically significant methylation sites by analysis, filtering of insignificant methylation sites, maintaining single-factor, multi-factor statistically significant DNA methylation sites as seed methylation sites, further using consistent cluster analysis, obtaining the number of molecular subtypes with stable clustering results, and finally obtaining several cluster-specific methylation sites by screening and dimensionality reduction. The dimensionality reduction method of DNA methylation spectrum for gastric cancer can effectively reduce the dimensionality of high-dimensional and redundant DNA methylation data, canselect key DNA methylation sites from hundreds of thousands of DNA methylation sites as biomarkers, and has great significance for genetic research and drug development of gastric cancer.
Owner:ZHEJIANG UNIV
Application of integrin beta4 gene DNA methylation site to preparation of biomarkers for early diagnosis of asthma and/or COPD
Owner:CENT SOUTH UNIV
DNA methylation data detection method and device thereof based on seed sequence information
ActiveCN108182348AQuick comparisonIncrease profitHybridisationSpecial data processing applicationsA-DNAConducting system
The invention provides a DNA methylation data detection method and a device thereof based on seed sequence information. The method comprises the steps of building an index database; obtaining sequencing data of a target sample, and according to the preset seed sequence length, dividing the sequencing data to obtain divided seed sequence information; based on the index database, determining comparison candidate position information of each divided seed sequence information; conducting system evaluation on each comparison candidate position information to obtain a system evaluation result, and according to the system evaluation result, obtaining a DNA methylation locus of the target sample. Time of comparison operation which consumes most time in data analysis is greatly shortened, on the basis of guaranteeing the integrity of a methylation detection area locus, the utilization rate of data is increased by a large margin, the operation efficiency and accuracy of the data are improved bya large margin, and great convenience is brought to further research on DNA nucleobase modification information for scientific research staff in the field of life science.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
Colorectal cancer DNA methylation marker, method for detecting colorectal cancer by using colorectal cancer DNA methylation marker and kit
InactiveCN108424968AEasy to detectLow costMicrobiological testing/measurementDNA/RNA fragmentationAKT2A-DNA
The invention discloses a colorectal cancer DNA methylation marker, a method for detecting the colorectal cancer by using the colorectal cancer DNA methylation marker, and a kit. The marker is methylation of gene FXYD1, DZIP3, RPS24, AKT2, UBTF, DAGLB, LPAR6, TP63, CX3CR1 and TACC2 sequences. The invention also discloses a probe, a method and a kit for detecting the DNA methylation marker, and a computer module for predicting the colorectal cancer occurrence risk by utilizing data of a DNA methylation site.
Owner:深圳市太科健康科技有限公司
Method for detecting additive and dominant genetic effects of DNA methylation sites on quantitative traits and application technology thereof
InactiveCN109554502ANucleotide librariesMicrobiological testing/measurementPopulation sampleQuantitative trait locus
Owner:BEIJING FORESTRY UNIVERSITY
Lung cancer recurrence prediction method based on DNA methylation of tissue-specific enhancement subregion
ActiveCN113436741AImprove uniformityGood forecastHealth-index calculationMicrobiological testing/measurementRecurrence predictionA-DNA
The invention relates to the field of biomedicine, discloses a lung cancer recurrence prediction method based on DNA methylation of a tissue-specific enhancement subregion, and is used for solving the problem that an existing non-small cell lung cancer recurrence model is unreasonable in non-small cell lung cancer recurrence prediction. The method comprises the following steps: firstly, extracting DNA of a lung cancer patient, and carrying out DNA methylation detection to obtain a beta value of a DNA methylation site of a tissue specific enhancer region; wherein the DNA (deoxyribonucleic acid) methylation sites comprise chr1: 170667082, chr12: 85280518, chr17: 76561412, chr11: 9759297, chr15: 91915828, chr16: 1079990, chr2: 226797988, and chr7: 150477419; and then substituting the beta value of the DNA methylation site into a pre-constructed lung cancer recurrence model, calculating a model score, and obtaining a prediction result according to the model score and a plurality of score thresholds. The method is suitable for predicting the recurrence of the early non-small cell lung cancer.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
A method for determining the role of the methylation site change of potato StALDH gene in low temperature stress
InactiveCN109182593AMicrobiological testing/measurementVector-based foreign material introductionBiotechnologyMethylation Site
The invention relates to a method for determining the role of the methylation site change of potato StALDH gene in low temperature stress, which includes the analysis of DNA methylation site of StALDHgene under low temperature stress, the analysis of expression level of StALDH gene under low temperature stress and the analysis of NbALDH function in plant development and response to low temperature stress. A low temperature stress response mechanism of potato is study from epigenetics field, A method for isolate genes invol in response to low temperature stress and changes of their methylationsites was developed, Therefore, cultivating potato varieties with cold tolerance and freeze resistance can resist the adverse effects of sudden low temperature on potato production, broaden the research on potato tolerance to low temperature stress, and have very important theoretical basis and practical guiding significance for ensuring high yield and stable harvest of potato in China. At the same time, it provides a theoretical reference for the role of DNA methylation modification in the response of other plants to stress.
Owner:INNER MONGOLIA UNIV OF SCI & TECH
Fluorescent biosensor for detecting DNA methylated transferase as well as preparation and application thereof
PendingCN113088558AImprove recognition efficiencyMicrobiological testing/measurementBiological material analysisEnzyme digestionFluorophore
The invention discloses a fluorescent biosensor for detecting DNA methylated transferase and preparation and application thereof. The fluorescent biosensor comprises a symmetric double-ring dumbbell and a 3D tetrahedral fluorescent scaffold, the symmetric double-ring dumbbell contains DNA methylation sites, methylation double strands can be formed under catalysis of DNA methylated transferase, enzyme digestion reaction is performed to form two single-chain dumbbell rings with consistent structures; the top ends of the 3D tetrahedral fluorescent scaffold contain the same hairpin and are modified with a fluorophore and a quenching group, the fluorophore and the quenching group are close to each other to cause fluorescence quenching, the sheared dumbbell ring can be combined with the hairpin to generate fluorescence, and DNA methylated transferase with different concentrations can generate fluorescence signals with different intensities through catalytic reaction. The DNA methylated transferase detection method established on the basis of the sensor is good in stability and specificity and high in sensitivity, can be used for screening MTase inhibitors, and has important significance on early detection and diagnosis of clinical cancers, drug research and the like.
Owner:CHONGQING MEDICAL UNIVERSITY
DNA methylation marker for Psoriatic Arthritis, diagnostic reagent and application thereof
ActiveCN112501287ALess blood samplesEasy to carry outMicrobiological testing/measurementDNA/RNA fragmentationA-DNADNA Methylation Site
The invention discloses a DNA methylation marker for Psoriatic Arthritis (PsA), a diagnostic reagent and application thereof. The DNA methylation marker comprises one or more of six methylation sites:chr14: 38061326, chr14: 38061320, chr9: 128585454, chr6: 37225002, chr3: 101901234 and chr6: 97369501. The specific DNA methylation sites are used as molecular markers for the first time to assist inscreening patients with Psoriatic Arthritis and Rheumatoid Arthritis (RA), and a new way and mode are opened up for diagnosis in the field. The DNA methylation sites are detected by using whole bloodof the patients, the purpose of early diagnosis of PsA is achieved, the required blood samples are few, the DNA methylation marker is convenient and easy to carry out, and the DNA methylation markerhas a good application prospect.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
GC tag-modified bisulfite genomic DNA sequencing for continuous methylation spectra
InactiveUS7851154B2Avoid the needMicrobiological testing/measurementFermentationGenomic sequencingCycle sequencing
The present invention relates to a tag-modified bisulfite genomic sequencing (tBGS) method developed for simplified evaluation of DNA methylation sites. The method employs direct cycle sequencing of PCR products at kilobase scale, without conventional DNA fragment cloning. The method entails subjecting bisulfite-modified genomic DNA to a second-round PCR amplification employing GC-tagged primers. The invention also relates to a method for identifying a patient at risk for lung cancer using the tBGS technique disclosed.
Owner:SPIVACK SIMON DANIEL +2
Prognostic risk assessment system for gastric cancer patients
PendingCN112908477APredict Prognostic SurvivalExcellent sensitivityHealth-index calculationProteomicsGastric carcinomaDifferential Methylation
A prognosis risk assessment system for gastric cancer patients is characterized by comprising a gastric cancer methylation data acquisition module, a differential methylation site acquisition module and a prognosis model construction module. The gastric cancer methylation data acquisition module is used for acquiring TCGA gastric cancer methylation spectrum and a gastric cancer methylation spectrum data set GSE30601, the differential methylation site acquisition module is used for obtaining a plurality of hyper-methylation sites and a plurality of hypo-methylation sites, and the prognosis model construction module is used for constructing a 11-DNA methylation site risk scoring formula of each patient.
Owner:黑龙江省医院
Methylation electrochemical immunoassay method, electrode and electrochemical sensor
PendingCN113533478ABiological testingMaterial electrochemical variablesImmune profilingAntiendomysial antibodies
The invention belongs to the technical field of immunoassay, and discloses a methylation electrochemical immunoassay method, an electrode and an electrochemical sensor. The methylation electrochemical immunoassay method comprises the steps of: preparing a nanogold modified gold electrode, and preparing the electrochemical sensor; and immobilizing the anti-5-mC antibody and the enzyme-labeled secondary antibody, and performing electrochemical determination. The preparation method of the nanogold-modified gold electrode comprises the following steps: polishing a gold electrode with the diameter of 2mm into a mirror surface by using 0.05 [mu]m Al2O3 powder, and then carrying out ultrasonic cleaning for 5 minutes in ultrapure water, absolute ethyl alcohol and ultrapure water respectively; after drying at room temperature, putting the electrode into a prepared Piranha solution to activate for more than 15 minutes, then thoroughly cleaning with ultrapure water, and blow-drying with nitrogen; and immersing the treated gold electrode in a HAuCl4. 3H2O solution, and finally, fuly washing and cleaning the gold electrode with ultrapure water, and preparing the modified gold electrode. Along with the increase of the number of DNA methylation sites, the peak current of the DPV is increased.
Owner:ARMY MEDICAL UNIV
DNA methylation index for early diagnosis and risk assessment of cancer and its application
The present invention relates to a method for cancer diagnosis and / or risk assessment of cancer in a subject, said method comprising the following steps: a) determining the The DNA methylation status at at least one DNA methylation site in; b) and compare the DNA methylation status at the DNA methylation site in the sample from the subject with that from the healthy control group The DNA methylation status at the corresponding DNA methylation site in the sample is compared, if there is a significant difference in the methylation status between the above two, it indicates that the subject has cancer or is suffering from at risk of cancer. The present invention also provides kits for the above methods.
Owner:TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
Method and DNA methylation marker for predicting calf muscle dimension decline risk in weightless muscle atrophy
The invention provides a DNA methylation marker for predicting the calf muscle dimension decline risk in weightless muscle atrophy. The DNA methylation marker comprises one or more of the following genes, and site annotation information thereof is shown in Table 3. The invention further provides a corresponding detection method. Excavation of the blood cell DNA methylation level and the calf muscle dimension finds that individual difference in human calf muscle dimension decline after weightlessness can be predicted through detection of the blood cell DNA methylation level, so that an individual which is more tolerant to a weightless condition is screened or calf muscle dimension change is scientifically researched. The invention provides a DNA methylation site set having a function of predicting the human calf muscle dimension decline risk after weightlessness.
Owner:SCI RES TRAINING CENT FOR CHINESE ASTRONAUTS
Time-of-flight mass spectrometry multi-target DNA methylation site quantitative detection method
InactiveCN112725425AThe result is accurateReduce experiment costMicrobiological testing/measurementMass Spectrometry-Mass SpectrometryBiochemistry
The invention belongs to the technical field of biology, particularly discloses a time-of-flight mass spectrometry multi-target DNA methylation site quantitative detection method, and provides a high-throughput detection method of DNA methylation sites, which can design a specific probe for multiple methylation sites to be detected, and in the same reaction system, a quantitative methylation degree detection result is obtained. The method has the characteristics that the operation is simple, the methylation sites in different regions can be simultaneously detected, the corresponding experiment cost is reduced, and the like.
Owner:博淼生物科技(北京)有限公司
Simple and convenient high-throughput DNA methylation detection method
PendingCN114381501AImprove targetingEasy to operateMicrobiological testing/measurementCytosineUracil
The invention provides a simple and convenient high-throughput DNA methylation detection method, which comprises the following steps: (1) carrying out oxidation treatment on a DNA sample by using strong base to oxidize cytosine in the DNA sample into uracil and oxidize methylated cytosine into thymine; (2) adding acid to neutralize strong base, and controlling the pH value of the reaction system within 6-8; and (3) carrying out library amplification and sequencing by adopting uracil-intolerant high-fidelity DNA polymerase. The invention develops a simple and convenient high-throughput DNA cytosine methylation detection technology which is named as DMA-seq. Compared with an existing DNA methylation detection kit, the DMA-seq has the advantages of being easy to operate, short in consumed time, small in DNA damage, good in data quality, high in methylation site targeting performance and the like, and is suitable for high-abundance DNA methylation site detection, especially in the early tumor screening direction.
Owner:YEASEN BIOTECHNOLOGY (SHANGHAI) CO LTD
DNA methylation site analysis method and DNA biosensor
PendingCN113481300AStrong specificityRealize quantitative analysisMicrobiological testing/measurementDNA/RNA fragmentationDiseaseDNA Methylation Site
The invention belongs to the field of biological genes technology, and discloses a DNA methylation site analysis method and a DNA biosensor. An AuNPs (at) rGO composite material is used for modifying a gold electrode; designing target sequences of a capture probe, an auxiliary probe and different methylation sites; performing DNA hybridization to induce signal amplification of gold nanoparticles aggregation; identifying a methylation site through anti-5methylcytosine antibody specifically; optimizing optimal experiment conditions of an electrochemical sensing analysis technology; performing electrochemical detection; and detecting the methylated DNA in the serum. According to the invention, a triple helix nucleic acid structure is combined with an electrochemical technology, a simple, stable and high-specificity DNA methylation site analysis technology is constructed, the maximum detection number of DNA methylation sites is 7, which is superior to results reported in other literatures, and a new technical means is provided for early clinical diagnosis of gene epigenetic disorder diseases and tumors and selection of a demethylation targeted therapy scheme.
Owner:ARMY MEDICAL UNIV
Whole genome typing method based on DNA methylation site genotypes
The invention discloses a whole genome typing method based on DNA methylation site genotypes. The whole genome typing method comprises the following steps: step 1, collecting a sample; step 2, establishing a DNA library; step 3, sequencing the library; step 4, identifying a site; and step 5, genotyping. In the step 2, MBD treatment of the combined methylation sensitive restriction endonuclease refers to that the endonuclease of a non-to-be-detected area and the methylation sensitive restriction endonuclease are used for digesting DNA fragments at the same time, then fragments containing methylation areas are captured and reserved through an MBD column, and in the step 1, at different time periods such as daytime and night in a group, compared with an existing genotyping method, the method has the advantages that the influence of environments in different time periods on the DNA methylation state can be judged; according to the invention, the change of the DNA methylation state in different growth states can be judged; and according to the method, two different methods for treating DNA are adopted, so that the genotyping accuracy is improved.
Owner:ARMY MEDICAL UNIV
Method and DNA methylation marker for predicting reduction risk of weightless bone loss carboxyterrninal propeptide of type I pmcollagen (PICP)
The invention provides a DNA methylation marker for predicting the reduction risk of weightless bone loss carboxyterrninal propeptide of type I pmcollagen (PICP). The DNA methylation marker includes one or more genes, and the annotation information of gene loci is shown in Table 3. The invention also provides a corresponding detection method. A result of the studying of the DNA methylation level of blood cells and the bone mineral density index (PICP) of serum shows that the DNA methylation level of the blood cells is detected to realize the predication of the individual difference in the decrease of the PICP of a weightless human body, so the method and the marker can be used to screen individuals having high tolerance to weight loss conditions or scientifically study the change of the PICP. A DNA methylation locus set which has a predictive function on the reduction risk of the PICP of the weightless human body is provided and is highly correlated with human body bone metabolism.
Owner:SCI RES TRAINING CENT FOR CHINESE ASTRONAUTS
dCas9-sgLINC00261 system for inhibiting pancreatic cancer progression, construction method and application
InactiveCN112029801ARich regulatory mechanismIncreased proliferationPeptide/protein ingredientsDigestive systemPancreas CancersOncology
The invention relates to the technical field of tumor molecular biology, and discloses a construction method of a dCas9-sgLINC00261 system. The method comprises the following steps: constructing a CRISPR-dCas9 pancreatic cancer cell line by using lentivirus, performing screening to obtain differential DNA methylation sites of a promoter region of LINC00261, constructing an sgRNA lentivirus vector,and transfecting the constructed sgRNA lentivirus vector into the CRISPR-dCas9 pancreatic cancer cell line. A dCas9-sgLINC00261 system is obtained. The invention also provides an application of the dCas9-sgLINC00261 system in preparation of drugs, markers or kits for preventing, detecting or treating pancreatic cancer. The cancer suppressor gene LINC00261 is modified through targeted demethylation, so that the endogenous expression quantity is increased, the pancreatic cancer proliferation and metastasis inhibiting capacity of the cancer suppressor gene is improved, and an innovative thoughtcan be provided for pancreatic cancer novel targeted drug research and development and clinical diagnosis and treatment.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
Detection and application of methylation sites of human FITM1 and HIST1H2BJ genes
ActiveCN112760382AAccurate quantitative detectionMicrobiological testing/measurementDNA/RNA fragmentationHepatocellular carcinomaMedicine
The invention provides detection and application of methylation sites of human FITM1 and HIST1H2BJ genes. The invention discovers specific DNA methylation sites of genes related to primary hepatocellular carcinoma population, including the methylation site cg06186808 of the FITM1 gene and the methylation site cg04424621 of the HIST1H2BJ gene, and designs a pyrosequencing PCR primer and a pyrosequencing primer for the specific sites, and methylation of the specific sites can be quickly and accurately quantitatively detected through pyrosequencing.
Owner:杨小丽
Application of dna methylation site of integrin β4 gene in preparation of biomarkers for early diagnosis of asthma and/or copd
Owner:CENT SOUTH UNIV
Methods, markers and kits for diagnosis, screening and risk prediction of colorectal cancer
ActiveCN108315418BEasy to detectLow costMicrobiological testing/measurementDNA/RNA fragmentationA-DNAOncology
The present invention discloses DNA methylation markers for diagnosis, screening and prediction of male colorectal cancer. The markers are group (1) or group (1) of the following three groups of CpG sites before and after the transcription start point of the gene RPS24 Group (1) methylated in combination with group (2) or group (3): +22, +27, and +29; (2)‑24, ‑18, +89, and +92; (3)+ 136, the sequence numbering is based on the numbering of the sequence shown in SEQ ID NO.1, wherein the A starting from the 143rd transcription start point is +1. The invention also discloses a probe, a method and a kit for detecting the DNA methylation marker, and a computer module for predicting the risk of male colorectal cancer by using the data of the DNA methylation site.
Owner:太科航天智能康养技术(深圳)有限责任公司
Human health and longevity markers based on specific peripheral blood DNA methylation sites and application of markers
InactiveCN111424098AImprove accuracyHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationMedicineGenetics
The invention discloses human health and longevity markers based on specific peripheral blood DNA methylation sites and an application of the markers. The total number of the human health and longevity markers is 90. A single, or two or more markers can be used for predicting human health and longevity, and the human health and longevity markers have the characteristics of high accuracy and high sensitivity. The AUC value of 14 sites exceeds 0.85, and thus the human health and longevity markers can be well used for evaluating the potential of individual health and longevity.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
DNA methylation markers, diagnostic reagents and application of psoriatic arthritis
ActiveCN112501287BLess blood samplesEasy to carry outMicrobiological testing/measurementDNA/RNA fragmentationMethylation SiteDNA Methylation Site
The invention discloses a DNA methylation marker for psoriatic arthritis (PsA), a diagnostic reagent and applications thereof. Including 6 methylation sites: one or more of chr14:38061326, chr14:38061320, chr9:128585454, chr6:37225002, chr3:101901234, chr6:97369501. The present invention uses specific DNA methylation sites as molecular markers for the first time to assist in the screening of psoriatic arthritis and rheumatoid arthritis (Rheumatoid Arthritis, RA) patients, opening up a new way for diagnosis in this field and way. The invention utilizes whole blood of patients to detect DNA methylation sites to achieve the purpose of early diagnosis of PsA, requires less blood samples, is convenient and easy to carry out, and has good application prospects.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com